CN103083429B - Blood fat-reducing traditional Chinese medicine formula - Google Patents
Blood fat-reducing traditional Chinese medicine formula Download PDFInfo
- Publication number
- CN103083429B CN103083429B CN201310001562.3A CN201310001562A CN103083429B CN 103083429 B CN103083429 B CN 103083429B CN 201310001562 A CN201310001562 A CN 201310001562A CN 103083429 B CN103083429 B CN 103083429B
- Authority
- CN
- China
- Prior art keywords
- extract
- extraction
- dry
- parts
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 239000008280 blood Substances 0.000 title claims abstract description 35
- 210000004369 blood Anatomy 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 135
- 238000000605 extraction Methods 0.000 claims abstract description 48
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 32
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 32
- 244000147058 Derris elliptica Species 0.000 claims abstract description 32
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- 239000000706 filtrate Substances 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 46
- 239000008367 deionised water Substances 0.000 claims description 41
- 229910021641 deionized water Inorganic materials 0.000 claims description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 37
- 239000012141 concentrate Substances 0.000 claims description 20
- 241001092040 Crataegus Species 0.000 claims description 16
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 16
- 238000009835 boiling Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- -1 ethyl acetate Ester Chemical class 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 239000003925 fat Substances 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000009427 jiangzhi Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗高血脂症的药物,具体是一种降血脂中药组方。该中药组方是由下列重量份数的原料组成:翅果油树叶片提取物100-150份、山楂提取物50-70份、制首乌提取物100-150份、决明子提取物80-120份。该中药组方中的各原料都是原料药物经干燥粉碎、超声提取、萃取、浓缩、冷冻干燥、研磨而成。本发明中药组方经动物试验及临床治疗证明,具有较强的降血脂作用。本发明中药是纯天然药物,具有起效快、治愈率高、无副作用的优点。一般高血脂患者服用半个月即见效果,疗效显著,总有效率高达96.5%。愈后再适当的巩固用药,高血脂愈后不再反弹,并能预防高血脂所引起的并发症。
The invention provides a medicine for treating hyperlipidemia, in particular a traditional Chinese medicine prescription for lowering blood fat. The traditional Chinese medicine prescription is composed of the following raw materials in parts by weight: 100-150 parts of Samara oil tree leaf extract, 50-70 parts of hawthorn extract, 100-150 parts of Shouwu extract, 80-120 parts of cassia seed extract share. Each raw material in the traditional Chinese medicine prescription is formed by drying and pulverizing raw materials, ultrasonic extraction, extraction, concentration, freeze-drying and grinding. The traditional Chinese medicine prescription of the present invention has been proved by animal experiments and clinical treatment to have strong effect of lowering blood fat. The traditional Chinese medicine of the invention is a pure natural medicine and has the advantages of fast onset of action, high cure rate and no side effects. Generally, patients with hyperlipidemia will see the effect after taking it for half a month, and the curative effect is remarkable, with the total effective rate as high as 96.5%. Properly consolidate medication after recovery, hyperlipidemia will not rebound after recovery, and can prevent complications caused by hyperlipidemia.
Description
技术领域 technical field
本发明涉及一种中药组方,属心血管疾病治疗技术领域,具体是一种降血脂中药组方。 The invention relates to a traditional Chinese medicine prescription, which belongs to the technical field of cardiovascular disease treatment, in particular to a traditional Chinese medicine prescription for lowering blood fat.
背景技术 Background technique
血脂为血浆中的中性脂肪(甘油三酯和胆固醇)和类脂(磷脂、糖脂、固醇、类固醇)的总称,是生命细胞的基础代谢必需物质。但血脂长期过高会引发高血脂症,即血脂异常,也称为高脂蛋白血症,是一种全身性疾病,其基本病理生理为:血中总胆固醇(TC)、甘油三酯(TG)过高或高密度脂蛋白胆固醇(HDL-C)过低。高血脂症是诱发冠心病、脉粥样硬化、高血压等心血管疾病的主要因素。全世界每年有1700万人(占到总死亡人数的50%)死于心血管疾病。高血脂发病原因与遗传因素、身体病变、饮食习惯、精神状态等密切相关。近年来,随着人们生活水平的提高,膳食结构中高热量食物比例明显增加,加之人们活动量的减少,高血脂症发病率不断增加,仅我国高血脂症患者就已达1.6亿,而且发病人数以平均每年增加1500万人的上升态势。如何防治高血脂症已成为人们日趋关注的一个健康问题。 Blood lipids are the general term for neutral fats (triglycerides and cholesterol) and lipids (phospholipids, glycolipids, sterols, steroids) in plasma, and are essential substances for the basic metabolism of living cells. However, long-term high blood lipids will cause hyperlipidemia, that is, dyslipidemia, also known as hyperlipoproteinemia, is a systemic disease, and its basic pathophysiology is: total cholesterol (TC) in blood, triglyceride (TG) ) is too high or high-density lipoprotein cholesterol (HDL-C) is too low. Hyperlipidemia is the main factor inducing coronary heart disease, atherosclerosis, hypertension and other cardiovascular diseases. Worldwide, 17 million people (accounting for 50% of all deaths) die of cardiovascular disease every year. The pathogenesis of hyperlipidemia is closely related to genetic factors, physical lesions, eating habits, and mental state. In recent years, with the improvement of people's living standards, the proportion of high-calorie foods in the dietary structure has increased significantly, coupled with the reduction in people's activity, the incidence of hyperlipidemia has continued to increase, and the number of patients with hyperlipidemia in my country alone has reached 160 million. With an average annual increase of 15 million people on the rise. How to prevent and treat hyperlipidemia has become a health problem that people pay close attention to day by day.
目前国内外临床上应用的调脂类中、西类药物很多。西药如非诺贝特、益多酯、呋喃甲氢龙、他汀类等,但以他汀类占主导地位,他汀类药物虽可有效降低血清胆固醇含量,但有报道称该药物与肌肉病变等有关。国内疗效较好的降脂中成药主要有:降脂灵片、通脉降脂片、软脉灵、脂必妥片、安络宁等,这些药物在治疗高血脂症方面发挥了很大的作用。但随着高血脂症患者数量的增加,开发安全有效的预防和治疗高血脂症的药物以满足临床需要仍具重要的现实意义。 At present, there are many Chinese and Western medicines for lipid-lowering clinically used at home and abroad. Western medicines such as fenofibrate, ydolate, furandrolone, statins, etc., but statins dominate. Although statins can effectively reduce serum cholesterol levels, there are reports that the drug is related to muscle lesions, etc. . Lipid-lowering Chinese patent medicines with good domestic curative effect mainly include: Jiangzhiling Tablets, Tongmai Jiangzhi Tablets, Ruanmailing Tablets, Zhibituo Tablets, Anluoning, etc. These drugs have played a great role in the treatment of hyperlipidemia. effect. However, with the increase in the number of patients with hyperlipidemia, it is still of great practical significance to develop safe and effective drugs for the prevention and treatment of hyperlipidemia to meet clinical needs.
发明内容 Contents of the invention
本发明的目的是为了解决上述问题,而提供一种降血脂中药组方。 The purpose of the present invention is in order to solve above-mentioned problem, and provides a kind of prescription of Chinese medicine for lowering blood fat.
本发明是通过以下技术方案实现的: The present invention is achieved through the following technical solutions:
一种降血脂中药组方,由下列重量份数的原料组成: A traditional Chinese medicine prescription for lowering blood fat, consisting of the following raw materials in parts by weight:
翅果油树叶片提取物100-150份、山楂提取物50-70份、制首乌提取物100-150份、决明子提取物80-120份。 100-150 parts of Samara oil tree leaf extract, 50-70 parts of hawthorn extract, 100-150 parts of Shouwu extract, and 80-120 parts of cassia seed extract.
组方中各原料药物的提取方法如下: The extraction method of each raw material drug in the prescription is as follows:
①翅果油树叶片提取物的提取方法:取翅果油树叶片,干燥粉碎至60-80目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g翅果油树叶片加入10-20ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可; ①Extraction method of oil tree leaf extract: take leaves of oil tree samaras, dry and crush them to 60-80 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30 minutes, the amount of ethanol added is 1g leaves of oil tree Add 10-20ml of ethanol; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, extract the combined filtrate with ethyl acetate, concentrate the extract to extract, and finally freeze-dry and grind it into powder;
②山楂提取物的提取方法:取山楂,干燥粉碎至60-80目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g山楂加入10-20ml 去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可; ②Extraction method of hawthorn extract: take hawthorn, dry and crush it to 60-80 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g hawthorn, add 10-20ml deionized water; repeat the above method Extract 3 times, combine the filtrates of the 3 times of ultrasonic extraction, concentrate the combined filtrate to extract, and finally freeze-dry and grind into powder;
③制首乌提取物的提取方法:取制首乌,干燥粉碎至60-80目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g制首乌加入10-20ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可; ③Extraction method of Shouwu extract: take Shouwu, dry and crush it to 60-80 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30min, the amount of ethanol added is 1g of Shouwu, add 10-20ml ethanol; Repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, concentrate the combined filtrate into an extract, and finally freeze-dry and grind it into powder;
④决明子提取物的提取方法:取决明子,干燥粉碎至60-80目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g决明子加入10-20ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可。 ④Extraction method of cassia seed extract: choose cassia seed, dry and crush to 60-80 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g cassia seed, add 10-20ml deionized water; repeat the above method Extract 3 times, combine the filtrates of the 3 times of ultrasonic extraction, extract the combined filtrates with ethyl acetate, concentrate the extract to extract, freeze-dry and grind into powder.
根据本发明降血脂中药组方来制备降血脂中药时,其制备方法简单,将本发明中药组方中的各原料药物按所述配比混合后,采用常规的中药制备方法进行制备即可,同时也可再添加药学上可接受的辅料赋予一定的剂型,如:胶囊剂、片剂、冲剂、滴丸剂、口服液、口含片、颗粒剂、散剂、混悬剂等。 When the blood lipid-lowering traditional Chinese medicine is prepared according to the present invention, the preparation method is simple. After mixing the raw materials in the traditional Chinese medicine prescription of the present invention according to the stated ratio, the traditional Chinese medicine preparation method is used for preparation. At the same time, pharmaceutically acceptable auxiliary materials can also be added to give certain dosage forms, such as: capsules, tablets, granules, dropping pills, oral liquids, buccal tablets, granules, powders, suspensions, etc.
从药理活性看,本发明中药组方中所含的各原料药物组分均含有有效降低血脂的药理活性成分。 From the perspective of pharmacological activity, each raw drug component contained in the traditional Chinese medicine prescription of the present invention contains pharmacologically active ingredients that can effectively reduce blood lipids.
翅果油树为胡秃子科植物,为我国第四季冰川作用后的孑遗植物之一。现有研究表明,翅果油树叶片中富含生物碱、黄酮、多糖及萜类化合物、Vc以及与人体健康密切相关的微量元素;且其叶片提取液有较强的抗氧化活性。另有当地居民常将其叶片泡水饮用,长期饮用有降血脂、降血压、可延年益寿之效。此外,经动物(大鼠)高血脂模型试验已表明饲喂上述翅果油树叶片提取物可有效降低大鼠血清总胆固醇(TC)和甘油三脂 (TG)的含量(图1-图2)。 Samara oil tree is a bald family plant, and it is one of the relict plants after the glaciation in the fourth season of our country. Existing studies have shown that the leaves of Samara oil tree are rich in alkaloids, flavonoids, polysaccharides and terpenoids, Vc and trace elements closely related to human health; and its leaf extract has strong antioxidant activity. In addition, local residents often soak the leaves in water for drinking. Long-term drinking has the effect of lowering blood fat, lowering blood pressure, and prolonging life. In addition, animal (rat) hyperlipidemia model experiments have shown that feeding the above-mentioned leaf extract of Samara oleifera can effectively reduce the content of total cholesterol (TC) and triglyceride (TG) in rat serum (Figure 1-Figure 2 ).
试验过程为:①高脂模型:取50只大鼠,喂高脂饲料(基础饲料78.6%、蛋黄粉10%、胆固醇1%、胆盐0.2%、猪油10%、甲巯眯唑片0.2%)30d,每天自由饮水和采食,30d后禁食不禁水,12h后尾静脉采血测血脂浓度,检测合格后作为高脂模型;②药效分析:将高血脂模型大鼠50只随机分为5组,每组10只,设置为:模型组、低、中、高剂量组(翅果油树叶片提取物)与脂必妥对照组,以同步饲养的健康大鼠10只作为空白对照组。日灌胃给药1次,空白组给等量生理盐水,分别于给药后第28天和第42天,实验前禁食不禁水12h,末次给药后2h采血,测血脂浓度。图中a、b、c、d分别表示组间差异显著性p<0.05。 The test process is as follows: ①High-fat model: Take 50 rats and feed them with high-fat diet (basic feed 78.6%, egg yolk powder 10%, cholesterol 1%, bile salt 0.2%, lard 10%, methimazole tablet 0.2 %) for 30 days, free to drink water and food every day, fasting after 30 days without water, blood lipid concentration was measured by tail vein blood collection after 12 hours, after the test passed, it was used as a hyperlipidemia model; ②Pharmacological analysis: 50 hyperlipidemia model rats were randomly divided into There are 5 groups, 10 rats in each group, set up as: model group, low, medium and high dose group (extract from leaves of Samara oleifera) and Zhibituo control group, and 10 healthy rats fed synchronously as blank control Group. Gastrointestinal administration once a day, the blank group was given the same amount of normal saline, respectively, on the 28th and 42nd day after administration, fasting without water for 12 hours before the experiment, blood was collected 2 hours after the last administration, and the blood lipid concentration was measured. In the figure, a, b, c, and d respectively represent the significant difference between groups at p<0.05.
山楂为蔷薇科植物,性微温,味酸,甘。富含三萜类、黄酮、熊果酸、皂苷、有机酸类等活性成分。大量研究已证实山楂中富含的三萜类及黄酮类化合物具有扩张血管、调节血脂和胆固醇含量的功效。 Hawthorn is a Rosaceae plant, slightly warm in nature, sour in taste and sweet in taste. Rich in active ingredients such as triterpenoids, flavonoids, ursolic acid, saponins, and organic acids. A large number of studies have confirmed that the triterpenoids and flavonoids rich in hawthorn have the effect of dilating blood vessels and regulating blood lipid and cholesterol levels.
制首乌为蓼科植物,性微温,味苦、甘、涩。含有二苯乙烯苷类、蒽醌类、黄酮类等多种可有效降低血脂活性的活性成分。现代研究发现,制首乌能够提高肝细胞转化和代谢胆固醇的能力,可调节血清胆固醇,降低血糖。 Shouwu is a Polygonaceae plant, slightly warm in nature, bitter, sweet and astringent. Contains stilbene glycosides, anthraquinones, flavonoids and other active ingredients that can effectively reduce blood lipid activity. Modern studies have found that making Shouwu can improve the ability of liver cells to transform and metabolize cholesterol, regulate serum cholesterol, and lower blood sugar.
决明子为豆科植物,性寒,味甘、苦。具有祛风散热,清肝明日,润肠通便的功效。现代药理研究表明决明子具有降血脂、降血压等作用,其降脂有效成分为其所含蒽醌类化合物。 Semen Cassiae is a leguminous plant, cold in nature, sweet and bitter in taste. It has the effects of expelling wind and dissipating heat, clearing the liver and brightening the day, moistening the intestines and laxative. Modern pharmacological studies have shown that Semen Cassiae has the effects of lowering blood fat and blood pressure, and its active ingredient for lowering blood fat is the anthraquinone compound it contains.
进一步地,本发明中药组方中各组分原料的优选重量份数为: Further, the preferred parts by weight of each component raw material in the Chinese medicine prescription of the present invention are:
翅果油树叶片提取物150份、山楂提取物50份、制首乌提取物150份、决明子提取物100份。 150 parts of Samara oil tree leaf extract, 50 parts of hawthorn extract, 150 parts of Shouwu extract, and 100 parts of cassia seed extract.
本发明中药组方中的各组分原料药物的最佳配比由正交试验优选获得(表1-表2): The optimal proportioning ratio of each component raw material drug in the Chinese medicine prescription of the present invention is preferably obtained by orthogonal experiments (Table 1-Table 2):
表1 组方不同配比对高脂模型大鼠血清TC含量的影响Table 1 Effects of different formula ratios on serum TC levels in hyperlipidemia model rats
注:血清TC含量为高脂模型大鼠培养末期测定结果均值。 Note: The serum TC content is the mean value of the test results at the end of the culture of the hyperlipidemia model rats.
表2 组方不同配比对高脂模型大鼠血清TG含量的影响Table 2 Effects of different formula ratios on serum TG levels in hyperlipidemia model rats
注:血清TG含量为高脂模大鼠型培养末期测定结果均值。 Note : The serum TG content is the mean value of the final test results of the high-fat model rat type culture.
由上述正交试验结果可知,本发明降血脂中药组方中,各原料药物的最佳配比为:翅果油树叶片提取物150份、山楂提取物50份、制首乌提取物150份、决明子提取物100份。 As can be seen from the results of the above-mentioned orthogonal test, in the Chinese medicine prescription for lowering blood fat of the present invention, the optimal proportioning ratio of each raw material drug is: 150 parts of the leaf extract of Samara oleifera, 50 parts of the hawthorn extract, and 150 parts of the Radix Polygoni Multiflori extract. , 100 parts of cassia seed extract.
本发明降血脂中药组方有较强的降血脂药效作用,该中药组方中各原料药物协同作用经动物(大鼠)高血脂模型试验分析证实具有较强的降血脂药效作用(表3): The blood fat-lowering traditional Chinese medicine prescription of the present invention has stronger blood-lipid-lowering medicinal effect, and the synergistic action of each raw material drug in the Chinese medicinal prescription has been confirmed to have stronger blood-lipid-lowering medicinal effect by animal (rat) hyperlipidemia model test analysis (Table 3):
表3 组方对高血脂大鼠血清血脂水平的影响(mmoLTable 3 Effects of prescriptions on serum lipid levels in hyperlipidemic rats (mmoL -1 -1 ))
本发明降血脂中药组方,经动物毒性试验表明饲喂本组方后被试动物(大鼠)未见任何毒性反应,被试动物(大鼠)各项生理与脏器组织与正常对照比较均无显著差异(表4-表6),一定程度上说明本中药组方安全可靠。 The traditional Chinese medicine formula for lowering blood fat of the present invention shows that no toxic reaction is seen in the tested animals (rats) after feeding the formula through animal toxicity tests, and the physiological and visceral tissues of the tested animals (rats) are compared with the normal control There was no significant difference (Table 4-Table 6), which to a certain extent shows that this Chinese medicine formula is safe and reliable.
表4 组方对大鼠终期血液学指标的影响Table 4 Effects of prescriptions on final hematological indicators in rats
表5组方对大鼠生化指标的影响The influence of table 5 prescription on rat biochemical index
表6组方对大鼠脏体比的影响The influence of table 6 prescription on rat viscera body ratio
为了表明本发明中药组方对高血脂症患者的治疗效果,本发明经86例系统临床观察。在上述临床观察的过程中,并对上述患者进行记录其病史、病情、年龄及疗效的工作。 In order to show the therapeutic effect of the traditional Chinese medicine prescription of the present invention on patients with hyperlipidemia, the present invention has undergone 86 systematic clinical observations. During the above-mentioned clinical observation process, record the medical history, condition, age and curative effect of the above-mentioned patients.
临床治疗效果的判断标准为: The criteria for judging clinical efficacy are:
治愈:症状、体征全部消失,化验指标均在正常范围。 Cure: Symptoms and signs all disappeared, and the laboratory indicators were all within the normal range.
好转:自觉症状如胸闷、腹胀、倦怠乏力、头晕头痛等基本消失,化验血脂接近正常值。 Improvement: subjective symptoms such as chest tightness, abdominal distension, fatigue, dizziness and headache basically disappeared, and blood lipids were close to normal.
无效:症状、体征、化验指标无明显改善。 Ineffective: Symptoms, signs, and laboratory indicators have not been significantly improved.
治疗结果:本发明中药组方经对86例高血脂症患者进行治疗,73例痊愈,10例好转,3例无效,总有效率达96.5%。 Treatment results: 86 patients with hyperlipidemia were treated with the traditional Chinese medicine formula of the present invention, 73 patients were cured, 10 patients took a turn for the better, 3 patients were ineffective, and the total effective rate reached 96.5%.
典型病例: Typical cases:
病例1 :患者张某,男,38 岁,患高血脂症2年,长期胸闷、心慌、乏力、头晕目眩,服用本发明中药八个月后,症状完全消失、化验血脂正常。随访一年未复发。 Case 1: patient Zhang, man, 38 years old, suffered from hyperlipidemia for 2 years, long-term chest tightness, palpitation, fatigue, dizziness, after taking the Chinese medicine of the present invention for eight months, the symptoms disappeared completely, and blood lipids in laboratory tests were normal. Follow up a case by regular visits to and do not recur in one year.
病例2 :患者陈某某,女,435岁,患高血脂症,经口服本发明药物六个月后,症状消失,化验血脂正常。随访一年未复发。 Case 2: patient Chen XX, female, 435 years old, suffers from hyperlipidemia, after oral medicine of the present invention six months, symptom disappears, and blood fat of laboratory test is normal. Follow up a case by regular visits to and do not recur in one year.
病例3 :患者杨某某,男,50 岁,患高血脂症3年,多方治疗无效,经口服本发明药物一年后,症状消失,化验血脂正常。随访一年未复发。 Case 3: patient Yang, male, 50 years old, suffered from hyperlipidemia for 3 years, and multiple treatments were ineffective. After taking the medicine of the present invention orally for one year, the symptoms disappeared, and the blood fat was normal. Follow up a case by regular visits to and do not recur in one year.
本发明的有益效果是:本发明中药是纯天然药物,具有起效快、治愈率高、无副作用的优点。一般高血脂患者服用半个月即见效果,疗效显著,总有效率高达96.5%。愈后再适当的巩固用药,高血脂愈后不再反弹,并能预防高血脂所引起的并发症。 The beneficial effects of the invention are: the traditional Chinese medicine of the invention is a pure natural medicine, and has the advantages of fast onset of action, high cure rate and no side effects. Generally, patients with hyperlipidemia will see the effect after taking it for half a month, and the curative effect is remarkable, with the total effective rate as high as 96.5%. Properly consolidate medication after recovery, hyperlipidemia will not rebound after recovery, and can prevent complications caused by hyperlipidemia.
附图说明 Description of drawings
图1为翅果油树叶片提取物对大鼠血清总胆固醇(TC)浓度的影响。 Figure 1 is the effect of the leaf extract of Samara oleifera on the serum total cholesterol (TC) concentration of rats.
图2为翅果油树叶片提取物对大鼠血清甘油三脂(TG)浓度的影响。 Figure 2 is the effect of the leaf extract of Samara oleifera on rat serum triglyceride (TG) concentration.
具体实施方式 Detailed ways
实施例1 Example 1
一种降血脂中药组方,由下列重量份数的原料组成(每份为1g): A traditional Chinese medicine prescription for lowering blood fat, which is composed of the following raw materials in parts by weight (each part is 1g):
翅果油树叶片提取物150g、山楂提取物50g、制首乌提取物150g、决明子提取物100g。 Samara oil tree leaf extract 150g, hawthorn extract 50g, Shouwu extract 150g, cassia seed extract 100g.
组方中各原料的提取方法如下: The extraction method of each raw material in the prescription is as follows:
①翅果油树叶片提取物的提取方法:取翅果油树叶片,干燥粉碎至60目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g翅果油树叶片加入17ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;②山楂提取物的提取方法:取山楂,干燥粉碎至70目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g山楂加入20ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;③制首乌提取物的提取方法:取制首乌,干燥粉碎至74目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g制首乌加入14ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;④决明子提取物的提取方法:取决明子,干燥粉碎至63目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g决明子加入15ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可。 ①Extraction method of the leaf extract of Samara oil tree: take the leaf of Samara oil tree, dry and crush it to 60 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30min, the amount of ethanol added is 1g of Samara oil tree leaf and 17ml Ethanol; Repeat the extraction 3 times according to the above method, combine the filtrates of the 3 ultrasonic extractions, extract the combined filtrates with ethyl acetate, concentrate the extracts into extracts, and finally freeze-dry them and grind them into powders; ② Hawthorn extract Extraction method: take hawthorn, dry and crush to 70 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g hawthorn and add 20ml deionized water; repeat the extraction 3 times according to the above method, and 3 times ultrasonically The extracted filtrates are combined, the combined filtrates are concentrated to an extract, and finally freeze-dried and ground into a powder; ③The extraction method of the Radix Polygoni Multiflori extract: take Radix Polygoni Multiflori, dry and crush it to 74 mesh, add 60% ethanol Ultrasonic extraction at 80°C for 30 minutes, adding 14ml of ethanol to 1 g of Shouwu; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, concentrate the combined filtrate into an extract, and finally freeze-dry Just grind it into powder; ④ Extraction method of cassia seed extract: take cassia seed, dry and crush to 63 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g cassia seed and 15ml deionized water; according to the above Methods The extraction was repeated 3 times, the filtrates of the 3 times of ultrasonic extraction were combined, the combined filtrates were extracted with ethyl acetate, the extract was concentrated to extract, and finally freeze-dried and ground into powder.
将上述各原料提取物粉末按:翅果油树叶片提取物150g、山楂提取物50g、制首乌提取物150g、决明子提取物100g充分混匀,可制作成为冲剂,服用时按药量开水冲服即可。 Mix the extract powders of the above raw materials: 150g of Samara oil tree leaf extract, 50g of hawthorn extract, 150g of Radix Polygoni Multiflori extract, and 100g of Semen Cassiae extract. That's it.
实施例2 Example 2
一种降血脂中药组方,由下列重量份数的原料组成(每份为1kg): A traditional Chinese medicine prescription for reducing blood fat, which is composed of the following raw materials in parts by weight (each part is 1kg):
翅果油树叶片提取物115 kg、山楂提取物70 kg、制首乌提取物120 kg、决明子提取物90kg。 Samara oil tree leaf extract 115 kg, hawthorn extract 70 kg, Shouwu extract 120 kg, cassia seed extract 90 kg.
组方中各原料的提取方法如下: The extraction method of each raw material in the prescription is as follows:
①翅果油树叶片提取物的提取方法:取翅果油树叶片,干燥粉碎至80目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g翅果油树叶片加入10ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;②山楂提取物的提取方法:取山楂,干燥粉碎至80目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g山楂加入12ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;③制首乌提取物的提取方法:取制首乌,干燥粉碎至60目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g制首乌加入10ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;④决明子提取物的提取方法:取决明子,干燥粉碎至72目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g决明子加入20ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可。 ①Extraction method of the leaf extract of Samara oil tree: take the leaf of Samara oil tree, dry and crush it to 80 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30min, the amount of ethanol added is 1g of Samara oil tree leaf and add 10ml Ethanol; Repeat the extraction 3 times according to the above method, combine the filtrates of the 3 ultrasonic extractions, extract the combined filtrates with ethyl acetate, concentrate the extracts into extracts, and finally freeze-dry them and grind them into powders; ② Hawthorn extract Extraction method: take hawthorn, dry and crush to 80 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g hawthorn and add 12ml deionized water; repeat the extraction 3 times according to the above method, and 3 times ultrasonically The extracted filtrates are combined, the combined filtrates are concentrated to an extract, and finally freeze-dried and ground into a powder; ③The extraction method of the Radix Polygoni Multiflori extract: take Radix Polygoni Multiflori, dry and crush it to 60 mesh, add 60% ethanol Ultrasonic extraction at 80°C for 30 minutes, adding 10ml of ethanol to 1 g of Shouwu; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, concentrate the combined filtrate into an extract, and finally freeze-dry Just grind it into powder; ④ Extraction method of cassia seed extract: take cassia seed, dry and crush to 72 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g cassia seed and 20ml deionized water; according to the above Methods The extraction was repeated 3 times, the filtrates of the 3 times of ultrasonic extraction were combined, the combined filtrates were extracted with ethyl acetate, the extract was concentrated to extract, and finally freeze-dried and ground into powder.
将上述各原料提取物粉末按:翅果油树叶片提取物115 kg、山楂提取物70 kg、制首乌提取物120 kg、决明子提取物90kg充分混匀,再粉碎成细粉,加入淀粉、微晶纤维素、低取代纤维素以70%的乙醇湿法制粒,压片,包衣即得片剂。 The extract powders of the above-mentioned raw materials were pressed: 115 kg of Samara oil tree leaf extract, 70 kg of hawthorn extract, 120 kg of Shouwu extract, and 90 kg of cassia seed extract, fully mixed, then crushed into fine powder, added starch, Microcrystalline cellulose and low-substituted cellulose are wet granulated with 70% ethanol, compressed into tablets, and coated to obtain tablets.
实施例3 Example 3
一种降血脂中药组方,由下列重量份数的原料组成(每份为1两): A traditional Chinese medicine prescription for reducing blood fat, which is composed of the following raw materials in parts by weight (each part is 1 tael):
翅果油树叶片提取物100两、山楂提取物65两、制首乌提取物135两、决明子提取物80两。 Samara oil tree leaf extract 100 taels, hawthorn extract 65 taels, Shouwu extract 135 taels, cassia seed extract 80 taels.
组方中各原料的提取方法如下: The extraction method of each raw material in the prescription is as follows:
①翅果油树叶片提取物的提取方法:取翅果油树叶片,干燥粉碎至75目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g翅果油树叶片加入13ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;②山楂提取物的提取方法:取山楂,干燥粉碎至65目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g山楂加入10ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;③制首乌提取物的提取方法:取制首乌,干燥粉碎至80目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g制首乌加入20ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;④决明子提取物的提取方法:取决明子,干燥粉碎至80目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g决明子加入17ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可。 ①Extraction method of the leaf extract of Samara oil tree: Take the leaf of Samara oil tree, dry and crush it to 75 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30 minutes, the amount of ethanol added is 1g of Samara oil tree leaf and add 13ml Ethanol; Repeat the extraction 3 times according to the above method, combine the filtrates of the 3 ultrasonic extractions, extract the combined filtrates with ethyl acetate, concentrate the extracts into extracts, and finally freeze-dry them and grind them into powders; ② Hawthorn extract Extraction method: take hawthorn, dry and crush it to 65 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g hawthorn and add 10ml deionized water; repeat the extraction 3 times according to the above method, and 3 times ultrasonically The extracted filtrates are combined, the combined filtrates are concentrated to an extract, and finally freeze-dried and ground into a powder; ③The extraction method of the Radix Polygoni Multiflori extract: take Radix Polygoni Multiflori, dry and crush it to 80 mesh, add 60% ethanol Ultrasonic extraction at 80°C for 30 minutes, the amount of ethanol added is 1 g of Shouwu, and 20 ml of ethanol is added; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, concentrate the combined filtrate into an extract, and finally freeze-dry Grind into powder; ④Extraction method of cassia seed extract: take cassia seed, dry and crush to 80 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g cassia seed and 17ml deionized water; according to the above Methods The extraction was repeated 3 times, the filtrates of the 3 times of ultrasonic extraction were combined, the combined filtrates were extracted with ethyl acetate, the extract was concentrated to extract, and finally freeze-dried and ground into powder.
将上述各原料提取物粉末按:翅果油树叶片提取物100两、山楂提取物65两、制首乌提取物135两、决明子提取物80两充分混匀,再粉碎成细粉,按常规方法制成胶囊剂即可。 The extract powders of the above raw materials were mixed according to: 100 taels of Samara oil tree leaf extract, 65 taels of hawthorn extract, 135 taels of Zhishouwu extract, and 80 taels of cassia seed extract, and then pulverized into fine powder. The method can be made into capsules.
实施例4 Example 4
一种降血脂中药组方,由下列重量份数的原料组成(每份为1斤): A traditional Chinese medicine prescription for reducing blood fat, which is composed of the following raw materials in parts by weight (each part is 1 catties):
翅果油树叶片提取物140斤、山楂提取物60斤、制首乌提取物100斤、决明子提取物120斤。 Samara oil tree leaf extract 140 catties, hawthorn extract 60 catties, Shouwu extract 100 catties, cassia seed extract 120 catties.
组方中各原料的提取方法如下:翅果油树叶片提取物的提取方法:取翅果油树叶片,干燥粉碎至65目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g翅果油树叶片加入20ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;②山楂提取物的提取方法:取山楂,干燥粉碎至60目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g山楂加入18ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;③制首乌提取物的提取方法:取制首乌,干燥粉碎至67目,加入60%的乙醇于80℃下超声提取30min,乙醇加入量为1g制首乌加入18ml乙醇;按上述方法重复提取3次,将3次超声提取的滤液合并,将合并滤液浓缩至浸膏状,最后冷冻干燥后研成粉末即可;④决明子提取物的提取方法:取决明子,干燥粉碎至60目,加入去离子水于沸水中超声提取40min,去离子水加入量为1g决明子加入10ml去离子水;按上述方法重复提取3次,将3次超声提取的滤液合并,合并滤液经乙酸乙酯萃取,将萃取液浓缩至浸膏状,最后冷冻干燥后研成粉末即可。 The extraction method of each raw material in the prescription is as follows: Extraction method of the leaf extract of Samara oil tree: take the leaf of Samara oil tree, dry and crush to 65 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30min, the amount of ethanol added Add 20ml of ethanol to 1g of Samara oil tree leaves; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, extract the combined filtrate with ethyl acetate, concentrate the extract to extract, finally freeze-dry and grind It can be made into powder; ②Extraction method of hawthorn extract: take hawthorn, dry and crush to 60 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g hawthorn and 18ml deionized water; according to the above method Repeat the extraction 3 times, combine the filtrates of the 3 times of ultrasonic extraction, concentrate the combined filtrate into an extract, and finally freeze-dry it and grind it into powder; To 67 mesh, add 60% ethanol and ultrasonically extract at 80°C for 30min. The amount of ethanol added is 1g of Shouwu and 18ml of ethanol is added; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, and concentrate the combined filtrate To the extract form, finally freeze-dried and ground into powder; ④ Extraction method of cassia seed extract: take cassia seed, dry and crush to 60 mesh, add deionized water and ultrasonically extract in boiling water for 40min, the amount of deionized water added is 1g Add 10ml of deionized water to the cassia seeds; repeat the extraction 3 times according to the above method, combine the filtrates of the 3 times of ultrasonic extraction, extract the combined filtrates with ethyl acetate, concentrate the extracts into extracts, and finally freeze-dry them and grind them into powders .
将上述各原料提取物粉末按:翅果油树叶片提取物140斤、山楂提取物60斤、制首乌提取物100斤、决明子提取物120斤充分混匀,按常规方法制成口服液即可。 The extract powders of the above-mentioned raw materials are pressed: 140 jin of Samara oleifera leaf extract, 60 jin of hawthorn extract, 100 jin of Shouwu extract, 120 jin of cassia seed extract, and make oral liquid according to the conventional method. Can.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310001562.3A CN103083429B (en) | 2013-01-04 | 2013-01-04 | Blood fat-reducing traditional Chinese medicine formula |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310001562.3A CN103083429B (en) | 2013-01-04 | 2013-01-04 | Blood fat-reducing traditional Chinese medicine formula |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103083429A CN103083429A (en) | 2013-05-08 |
CN103083429B true CN103083429B (en) | 2014-10-08 |
Family
ID=48196908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310001562.3A Expired - Fee Related CN103083429B (en) | 2013-01-04 | 2013-01-04 | Blood fat-reducing traditional Chinese medicine formula |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103083429B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106262876A (en) * | 2016-08-08 | 2017-01-04 | 司鸿娟 | A kind of multi-functional samara oil oral liquid and preparation method thereof |
CN107509907A (en) * | 2017-10-18 | 2017-12-26 | 山西琪尔康翅果生物制品有限公司 | A kind of solid beverage with preventing alcoholic liver injury |
CN111758809A (en) * | 2020-06-30 | 2020-10-13 | 郑屹 | Astragalus membranaceus and samara leaf health-care tea |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1143516A (en) * | 1996-04-05 | 1997-02-26 | 何志信 | Balanced nutritious food-kangfusu and preparing process thereof |
CN1631480A (en) * | 2004-11-19 | 2005-06-29 | 中国科学院山西煤炭化学研究所 | Method for extracting samara essence with supercritical CO2 |
CN1660287A (en) * | 2004-12-08 | 2005-08-31 | 郭来旺 | Capsule for descend of blood fat and preparing method |
CN1788757A (en) * | 2005-10-18 | 2006-06-21 | 安微济人药业有限公司 | Hyperlipemia-treating Chinese traditional medicinal tablet and its preparation process |
CN1911334A (en) * | 2006-07-28 | 2007-02-14 | 湖南恒伟药业有限公司 | Traditional Chinese medicine composition for lowering blood fat, and prepn. method therefor |
CN101698032A (en) * | 2008-12-09 | 2010-04-28 | 浙江天一堂集团有限公司 | Method for preparing tablets for treating hyperlipemia and prepared product |
CN102085305A (en) * | 2009-12-02 | 2011-06-08 | 彭伟洪 | Dripping pill capable of reducing fat |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0873369A (en) * | 1994-09-01 | 1996-03-19 | Fuairudo:Kk | Tea for health |
JPH09208480A (en) * | 1995-12-01 | 1997-08-12 | Kao Corp | Substance P antagonist |
AUPS323902A0 (en) * | 2002-06-27 | 2002-07-18 | Chinese Medicines Scientific Consultants Pty Ltd | Compositions and methods for treating gynaecological disorders |
-
2013
- 2013-01-04 CN CN201310001562.3A patent/CN103083429B/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1143516A (en) * | 1996-04-05 | 1997-02-26 | 何志信 | Balanced nutritious food-kangfusu and preparing process thereof |
CN1631480A (en) * | 2004-11-19 | 2005-06-29 | 中国科学院山西煤炭化学研究所 | Method for extracting samara essence with supercritical CO2 |
CN1660287A (en) * | 2004-12-08 | 2005-08-31 | 郭来旺 | Capsule for descend of blood fat and preparing method |
CN1788757A (en) * | 2005-10-18 | 2006-06-21 | 安微济人药业有限公司 | Hyperlipemia-treating Chinese traditional medicinal tablet and its preparation process |
CN1911334A (en) * | 2006-07-28 | 2007-02-14 | 湖南恒伟药业有限公司 | Traditional Chinese medicine composition for lowering blood fat, and prepn. method therefor |
CN101698032A (en) * | 2008-12-09 | 2010-04-28 | 浙江天一堂集团有限公司 | Method for preparing tablets for treating hyperlipemia and prepared product |
CN102085305A (en) * | 2009-12-02 | 2011-06-08 | 彭伟洪 | Dripping pill capable of reducing fat |
Non-Patent Citations (6)
Title |
---|
JP特开平873369A 1996.03.19 |
JP特开平9208480A 1997.08.12 |
张直峰等.翅果油树不同部位总黄酮含量及抗氧化活性比较研究.《"第二届中草药提取关键技术与提取物产业应用"研讨会》.2009,第137-141页. |
清脂颗粒制备与鉴别方法研究;黄志海等;《数理医药学杂志》;20081231;第21卷(第3期);第340-341页,尤其是第340页左栏第1段,第341页左栏第2.1节 * |
翅果油树不同部位总黄酮含量及抗氧化活性比较研究;张直峰等;《"第二届中草药提取关键技术与提取物产业应用"研讨会》;20091231;第137-141页,尤其是第138页第2.1部分,第138页第1.2.1节 * |
黄志海等.清脂颗粒制备与鉴别方法研究.《数理医药学杂志》.2008,第21卷(第3期),第340-341页. |
Also Published As
Publication number | Publication date |
---|---|
CN103083429A (en) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101239112A (en) | Traditional Chinese medicine composition for regulating blood lipid and preparation method thereof | |
CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
CN102688295A (en) | Chinese medicine composition for controlling metabolic diseases as well as preparation method and application thereof | |
CN100525791C (en) | Health product and medicine and their preparing method | |
CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
CN106924374B (en) | A composition and its preparation method and its application in the preparation of hypoglycemic and/or hypolipidemic products | |
CN115317574A (en) | Composition for treating hyperuricemia and application thereof | |
CN102319289B (en) | Hyperglycemic Chinese medicinal composition comprising cinnamon polyphenol and the like and preparation method of hyperglycemic Chinese medicinal composition | |
CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
CN107773679A (en) | A kind of composition and its preparation technology for aiding in reducing blood lipid, aiding in thrombus | |
CN112089783B (en) | Application of traditional Chinese medicine composition in the preparation of medicine for preventing or/and treating obesity | |
CN100536905C (en) | A kind of traditional Chinese medicine composition for treating epigastric pain disease | |
CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
CN111700927A (en) | A kind of medicine and food homologous composition with hypoglycemic effect and its preparation method and application | |
CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
CN105193993B (en) | A kind of traditional Chinese medicine composition with hypolipidemic effect and its preparation method and use | |
CN103623109A (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
KR102675725B1 (en) | Herbal pill composition for anti-inflammatory and immune enhancement containing Paeonia lactiflora and Cinnamomum cassia Blume and its preparation method | |
CN113893316B (en) | Application of traditional Chinese medicine composition in preparation of medicine for improving chronic fatigue symptoms of damp and hot people | |
CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
CN103463414A (en) | Pharmaceutical composition for treating fatty liver and application thereof | |
CN106581142A (en) | Compound traditional Chinese medicine composition capable of regulating blood fat and purpose thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141008 Termination date: 20160104 |
|
EXPY | Termination of patent right or utility model |